ICER received a new grant from the California Health Care Foundation (CHCF) to develop 1) two annual unsupported price increase reports specific to California, and 2) a policymaker guide outlining how to use comparative effectiveness research to ensure that patients have fair access to fairly priced drugs.

California passed SB-17, a drug transparency law requiring manufacturers to report increases to prescription drugs’ wholesale acquisition cost (WAC). ICER will leverage the annual SB-17 reports on brand and specialty drugs with the most significant year-over-year spending increases to evaluate whether there is new evidence that could justify the price increase (using the same methodology used for our annual unsupported price increase report at the national level). 

For questions or additional information, please contact Laura Cianciolo, Program Manager at